Medication info
Pregabalin Capsules 75 mg (Pregabalin)

Pregabalin Capsules 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Dongbang FTL Co., Ltd.
Appearance
A solid capsule with a reddish-brown upper part and white lower part containing white powder that is white or light yellow in color
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201900636 · Approved 2019.01.24 · Insurance code 680500730

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine should be administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See Section 5. Patients with Renal Impairment.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See Section 4. Discontinuation of Treatment.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose adjusted according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin a Starting dose (mg/day) 150, maximum dose (mg/day) 600, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Total daily dose of pregabalin a Starting dose (mg/day) 75, maximum dose (mg/day) 300, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Total daily dose of pregabalin a Starting dose (mg/day) 25-50, maximum dose (mg/day) 150, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalin a Starting dose (mg/day) 25, maximum dose (mg/day) 75, QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) In elderly patients with impaired renal function, dose reduction may be necessary.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Dongbang FTL Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used in adults for the treatment of peripheral and central neuropathic pain. It is also used as an adjunct for partial seizures that may or may not be accompanied by secondary generalization in epilepsy patients. Additionally, it helps alleviate symptoms in fibromyalgia patients. In summary, this drug is used for neuropathic pain, adjunct therapy for partial seizures in epilepsy, and fibromyalgia.

How to take

Adult dose

This medicine should be administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See Section 5. Patients with Renal Impairment.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See Section 4. Discontinuation of Treatment.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose adjusted according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin a Starting dose (mg/day) 150, maximum dose (mg/day) 600, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Total daily dose of pregabalin a Starting dose (mg/day) 75, maximum dose (mg/day) 300, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Total daily dose of pregabalin a Starting dose (mg/day) 25-50, maximum dose (mg/day) 150, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalin a Starting dose (mg/day) 25, maximum dose (mg/day) 75, QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) In elderly patients with impaired renal function, dose reduction may be necessary.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or actions; thus, any changes in mood or behavior during treatment should be reported to a healthcare professional immediately. Do not take this medication if you have hypersensitivity to it or if you have certain genetic lactose intolerance disorders. Diabetic patients should be cautious as they may need to adjust the dosages of blood sugar control medications due to weight gain. If symptoms of angioedema appear, discontinue the medication immediately, and elderly patients should be cautious of the risk of falls due to dizziness and drowsiness. Consult a healthcare professional if you experience blurred vision or changes in eyesight while taking the medication. Withdrawal symptoms such as insomnia, headache, and anxiety may occur upon stopping the medication, so it should not be discontinued abruptly. Patients with a history of drug abuse should use this medication cautiously, and any unusual behavior should be reported to a healthcare professional. Patients with impaired kidney function may require dose adjustments. Patients with severe heart disease should use this medication with caution. Taking this medication in conjunction with other central nervous system depressants or opioid analgesics may increase the risk of respiratory depression, so caution is needed. Pregnant women are advised against taking this medication in early pregnancy due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Breastfeeding women should consider stopping breastfeeding or discontinuing the medication as it may pass into breast milk. Before engaging in hazardous activities such as driving or operating machinery, check whether this medication causes dizziness or drowsiness. If you experience severe rashes or allergic reactions on the skin, discontinue the medication immediately and consult a healthcare professional. In the event of an overdose, symptoms such as altered consciousness, drowsiness, or depression may occur, requiring immediate medical attention and possibly treatments such as dialysis. Children and elderly patients may be more sensitive to the effects and side effects of this medication, so caution is necessary when administering it. This drug is not metabolized and is primarily excreted via urine, thus requiring potential dose adjustments depending on kidney function.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • edema around the mouth
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 173 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • hypoglycemia
  • increased appetite
  • decreased appetite
  • confusion
  • disorientation
  • irritability
  • elation
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • anxiety
  • mood swings
  • emotional downturn
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • memory loss
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory deficit
  • sedation
  • drowsiness syndrome
  • cognitive impairment
  • nystagmus
  • language disorder
  • myoclonus
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • orthostatic dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • muscular weakness
  • olfactory disturbances
  • taste loss
  • writing impairment
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disturbance
  • incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait disturbance
  • falling
  • sensation of drunkenness
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • agitation
  • restlessness
  • exacerbation of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, and the storage temperature should be maintained between 15°C and 30°C. Proper storage will help preserve the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

A solid capsule with a reddish-brown upper part and white lower part containing white powder that is white or light yellow in color

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.